Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Mol Sci. 2013 May 24;14(6):11034-60. doi: 10.3390/ijms140611034.

Current status of biomarkers for prostate cancer.

Author information

1
Bosch Institute, the University of Sydney, Sydney 2006, Australia. cris.dosremedios@sydney.edu.au.

Abstract

Prostate cancer (PCa) is a leading cause of cancer-related death of men globally. Since its introduction, there has been intense debate as to the effectiveness of the prostate specific antigen (PSA) test as a screening tool for PCa. It is now evident that the PSA test produces unacceptably high rates of false positive results and is not prognostic. Here we review the current status of molecular biomarkers that promise to be prognostic and that might inform individual patient management. It highlights current efforts to identify biomarkers obtained by minimally invasive methods and discusses current knowledge with regard to gene fusions, mRNA and microRNAs, immunology, and cancer-associated microparticles.

PMID:
23708103
PMCID:
PMC3709717
DOI:
10.3390/ijms140611034
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Support Center